Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

126 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Antisense oligonucleotide targeting DMPK in patients with myotonic dystrophy type 1: a multicentre, randomised, dose-escalation, placebo-controlled, phase 1/2a trial.
Thornton CA, Moxley RT 3rd, Eichinger K, Heatwole C, Mignon L, Arnold WD, Ashizawa T, Day JW, Dent G, Tanner MK, Duong T, Greene EP, Herbelin L, Johnson NE, King W, Kissel JT, Leung DG, Lott DJ, Norris DA, Pucillo EM, Schell W, Statland JM, Stinson N, Subramony SH, Xia S, Bishop KM, Bennett CF. Thornton CA, et al. Among authors: moxley rt 3rd. Lancet Neurol. 2023 Mar;22(3):218-228. doi: 10.1016/S1474-4422(23)00001-7. Lancet Neurol. 2023. PMID: 36804094 Clinical Trial.
Milestones of progression in myotonic dystrophy type 1 and type 2.
Hamel JI, McDermott MP, Hilbert JE, Martens WB, Luebbe E, Tawil R, Moxley RT 3rd, Thornton CA. Hamel JI, et al. Among authors: moxley rt 3rd. Muscle Nerve. 2022 Oct;66(4):508-512. doi: 10.1002/mus.27674. Epub 2022 Jul 21. Muscle Nerve. 2022. PMID: 35778789
Brief assessment of cognitive function in myotonic dystrophy: Multicenter longitudinal study using computer-assisted evaluation.
Deutsch GK, Hagerman KA, Sampson J, Dent G, Dekdebrun J, Parker DM, Thornton CA, Heatwole CR, Subramony SH, Mankodi AK, Ashizawa T, Statland JM, Arnold WD, Moxley RT 3rd, Day JW; Myotonic Dystrophy Clinical Research Network. Deutsch GK, et al. Among authors: moxley rt 3rd. Muscle Nerve. 2022 May;65(5):560-567. doi: 10.1002/mus.27520. Epub 2022 Feb 28. Muscle Nerve. 2022. PMID: 35179228 Free PMC article.
Patient-reported study of the impact of pediatric-onset myotonic dystrophy.
Hunter M, Ekstrom AB, Campbell C, Hung M, Bounsanga J, Bates K, Adams HR, Luebbe E, Moxley RT 3rd, Heatwole C, Johnson NE. Hunter M, et al. Among authors: moxley rt 3rd. Muscle Nerve. 2019 Oct;60(4):392-399. doi: 10.1002/mus.26632. Epub 2019 Jul 26. Muscle Nerve. 2019. PMID: 31298737 Free PMC article.
Survival patterns and cancer determinants in families with myotonic dystrophy type 1.
Best AF, Hilbert JE, Wood L, Martens WB, Nikolenko N, Marini-Bettolo C, Lochmüller H, Rosenberg PS, Moxley RT 3rd, Greene MH, Gadalla SM. Best AF, et al. Among authors: moxley rt 3rd. Eur J Neurol. 2019 Jan;26(1):58-65. doi: 10.1111/ene.13763. Epub 2018 Sep 16. Eur J Neurol. 2019. PMID: 30051542 Free PMC article.
High frequency of gastrointestinal manifestations in myotonic dystrophy type 1 and type 2.
Hilbert JE, Barohn RJ, Clemens PR, Luebbe EA, Martens WB, McDermott MP, Parkhill AL, Tawil R, Thornton CA, Moxley RT 3rd; National Registry Scientific Advisory Committee/Investigators. Hilbert JE, et al. Among authors: moxley rt 3rd. Neurology. 2017 Sep 26;89(13):1348-1354. doi: 10.1212/WNL.0000000000004420. Epub 2017 Aug 30. Neurology. 2017. PMID: 28855409 Free PMC article.
Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy.
Griggs RC, Miller JP, Greenberg CR, Fehlings DL, Pestronk A, Mendell JR, Moxley RT 3rd, King W, Kissel JT, Cwik V, Vanasse M, Florence JM, Pandya S, Dubow JS, Meyer JM. Griggs RC, et al. Among authors: moxley rt 3rd. Neurology. 2016 Nov 15;87(20):2123-2131. doi: 10.1212/WNL.0000000000003217. Epub 2016 Aug 26. Neurology. 2016. PMID: 27566742 Free PMC article. Clinical Trial.
126 results